Dexcom (DXCM)Director sold ~$61K
Bridgette P Heller, Director at Dexcom, sold ~$61K of Dexcom shares.
- ~$61K
- Approx. value · 1,012 sh @ $60.01
- 25K
- Holds after · shares reported
- Traded
- May 12, 2026
- Filed
- May 14, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 16, 2026InsiderOfficer sold ~$110K of DXCM shares in the open market
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM watchOS App Model/Catalog Number: SW13355 Software Version: Versions 2.9…
- Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM iOS App Model/Catalog Number: SW12300 Software Version: Versions 2.9.0 t…
- Apr 14, 2026FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ iOS CGM App Model/Catalog Number: SW14244 Software Version: versions 1.5…
- Apr 15, 2026InsiderOfficer sold ~$107K of DXCM shares in the open market
- Apr 29, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.0%
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- Apr 29, 2026CongressDisclosed partial sale of DXCM — reported range $100,001 - $250,000
- Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
- May 7, 2026CongressDisclosed sale of DXCM — reported range $100,001 - $250,000
- May 12, 2026 · this disclosureInsiderDirector sold ~$61K of DXCM shares in the open market
What came next
- May 15, 2026InsiderOfficer sold ~$102K of DXCM shares in the open market
- May 21, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
- May 21, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
- May 27, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 US Retail Sensor/Transmitter 1-pack Model/Catalog Number: STP-AT-012 Softwar…
- Jun 3, 2026InsiderOfficer sold ~$359K of DXCM shares in the open market
- Jun 4, 2026InsiderOfficer sold ~$364K of DXCM shares in the open market
- Jun 8, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System
- Jun 12, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
- Jun 15, 2026Insider · 2 peopleInsiders: 3 sales (~$425K)
- Jul 6, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
- Jul 15, 2026InsiderOfficer sold ~$127K of DXCM shares in the open market
- Jul 20, 2026InsiderChair sold ~$2.04M of DXCM shares in the open market
- Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
- Jul 31, 2026InsiderDirector sold ~$160K of DXCM shares in the open market
- Aug 3, 2026InsiderDirector sold ~$171K of DXCM shares in the open market
- Aug 11, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
- Aug 12, 2026InsiderDirector sold ~$89K of DXCM shares in the open market
- Aug 14, 2026InsiderOfficer sold ~$156K of DXCM shares in the open market
- Aug 20, 2026Insider · 1 personInsiders: 3 sales (~$2.4M)
- Aug 27, 2026InsiderOfficer sold ~$227K of DXCM shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Dexcom
For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.
Other recent filings by Bridgette P Heller, Director
- SEC Form 4 at Dexcom (DXCM)Aug 13, 2026
- SEC Form 4 at Dexcom (DXCM)Feb 17, 2026
- SEC Form 4 at Dexcom (DXCM)Nov 12, 2025
- SEC Form 4 at Dexcom (DXCM)Mar 19, 2025
- SEC Form 4 at Dexcom (DXCM)Dec 17, 2024
The full history of Bridgette P Heller, Director is on the profile page.
How this filing works
Other disclosures at Dexcom
- SEC Form 4Sep 30, 2026
- SEC Form 144Sep 28, 2026
- SEC Form 4Sep 16, 2026
- SEC Form 4Sep 16, 2026
- SEC Form 4Sep 16, 2026
- SEC Form 144Sep 15, 2026
Everything OQRO holds on this company is on its DXCM page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
